|
Novo Nordisk and Valo Health Expand AI-Powered Partnership to Address Cardiometabolic Diseases
|
Written by: J. Smith |
Hits: 901
|
|
Semaglutide 7.2 mg Demonstrates Greater Weight Loss but Faces Market Challenges
|
Written by: J. Smith |
Hits: 823
|
|
2025 Outlook: GLP-1 Supply Gains Momentum Amid Expansion Efforts
|
Written by: J. Smith |
Hits: 5573
|
|
Abbott and Dexcom Settle Global Patent Disputes Over CGM Technologies
|
Written by: J. Smith |
Hits: 1309
|
|
Novo Nordisk’s CagriSema Falls Short of Investor Expectations Despite Promising Weight-Loss Results
|
Written by: J. Smith |
Hits: 907
|
|
FDA Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity
|
Written by: J. Smith |
Hits: 982
|
|
Possible Link Between Semaglutide and Vision Loss Raises Questions
|
Written by: J. Smith |
Hits: 1146
|
|
Dexcom Launches First Generative AI Platform in Glucose Biosensing
|
Written by: J. Smith |
Hits: 1036
|
|
Eli Lilly and Novo Nordisk Ramp Up GLP-1 Manufacturing Capacity
|
Written by: J. Smith |
Hits: 1867
|
|
Novo Nordisk to Slash US Insulin Prices in 2026
|
Written by: J. Smith |
Hits: 2090
|
